Treatment of lymphangiomas with OK-432 (Picibanil)
To determine the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas. The treatment was begun for 14 patients with lymphangioma. The age range of the patients at the time of the first injection was from 10 months to 42 years. Eleven of the lesions involved the head and neck region, tw...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular and interventional radiology 2003-01, Vol.26 (1), p.31-36 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36 |
|---|---|
| container_issue | 1 |
| container_start_page | 31 |
| container_title | Cardiovascular and interventional radiology |
| container_volume | 26 |
| creator | RAUTIO, Riitta KESKI-NISULA, Leo LARANNE, Jussi LAASONEN, Erkki |
| description | To determine the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
The treatment was begun for 14 patients with lymphangioma. The age range of the patients at the time of the first injection was from 10 months to 42 years. Eleven of the lesions involved the head and neck region, two the thorax and one was localized in the extremity. Prior to treatment all patients were investigated with either magnetic resonance imaging, computed tomography, ultrasound or a combination of these modalities. The injections were performed with ultrasound and/or fluoroscopic guidance. Eight patients received OK-432 as first-line treatment; five were treated after surgery and one after medical therapy. On average, 2.2 intracystic injections were performed per patient. Nine of the lesions were macrocystic and five were mixed lesions.
Eleven patients showed complete or marked response to the OK-432 sclerotherapy, two patients had moderate shrinkage of their lesions and only one patient showed no response to therapy. Macrocystic lesions showed the best response to therapy. Those patients who received OK-432 as first-line treatment showed complete or marked response.
It was found that treatment of lymphangiomas with OK-432 was safe and effective. |
| doi_str_mv | 10.1007/s00270-002-1980-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21088421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2142833071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-9defc1ed517fe77f988f70c677d30d7470f652ee732add5566ef8bfb675535423</originalsourceid><addsrcrecordid>eNpd0E1rGzEQBmBRGhrXzQ_opSwtLelByYy-9xhM0oQEkoMDuQlZK9UK--Gu1oT8-yjYYOhl5vLMi_QS8hXhDAH0eQZgGmiZFGsDlH8gMxScUTDq6SOZAWpBUUo8Jp9zfgZAaZj8RI6RiRqBwYyw5Rjc1IV-qoZYta_dZu36v2noXK5e0rSu7m9pSaxOH5JPK9en9vcXchRdm8PJfs_J49XlcnFN7-7_3Cwu7qjnhk20bkL0GBqJOgatY21M1OCV1g2HRgsNUUkWgubMNY2USoVoVnGltJRcCsbn5Mcud8hTstmnKfi1H_o--MkyBGMEw6J-7dRmHP5tQ55sl7IPbev6MGyz1RxqBVwX-P0_-Dxsx778wGqJRqpa1AXhDvlxyHkM0W7G1Lnx1SLY987trnNbpn3v3PJy820fvF11oTlc7Esu4OceuOxdG0fX-5QPTigQsrzxDRdFhXk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>751856949</pqid></control><display><type>article</type><title>Treatment of lymphangiomas with OK-432 (Picibanil)</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>RAUTIO, Riitta ; KESKI-NISULA, Leo ; LARANNE, Jussi ; LAASONEN, Erkki</creator><creatorcontrib>RAUTIO, Riitta ; KESKI-NISULA, Leo ; LARANNE, Jussi ; LAASONEN, Erkki</creatorcontrib><description>To determine the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
The treatment was begun for 14 patients with lymphangioma. The age range of the patients at the time of the first injection was from 10 months to 42 years. Eleven of the lesions involved the head and neck region, two the thorax and one was localized in the extremity. Prior to treatment all patients were investigated with either magnetic resonance imaging, computed tomography, ultrasound or a combination of these modalities. The injections were performed with ultrasound and/or fluoroscopic guidance. Eight patients received OK-432 as first-line treatment; five were treated after surgery and one after medical therapy. On average, 2.2 intracystic injections were performed per patient. Nine of the lesions were macrocystic and five were mixed lesions.
Eleven patients showed complete or marked response to the OK-432 sclerotherapy, two patients had moderate shrinkage of their lesions and only one patient showed no response to therapy. Macrocystic lesions showed the best response to therapy. Those patients who received OK-432 as first-line treatment showed complete or marked response.
It was found that treatment of lymphangiomas with OK-432 was safe and effective.</description><identifier>ISSN: 0174-1551</identifier><identifier>EISSN: 1432-086X</identifier><identifier>DOI: 10.1007/s00270-002-1980-3</identifier><identifier>PMID: 12491020</identifier><identifier>CODEN: CAIRDG</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Adult ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; CHEST ; Child ; Child, Preschool ; COMPUTERIZED TOMOGRAPHY ; Diseases of the cardiovascular system ; Female ; HEAD ; Humans ; Infant ; INJECTION ; Lymphangioma - drug therapy ; Lymphangioma - pathology ; Male ; Medical sciences ; NECK ; NMR IMAGING ; PATIENTS ; Picibanil - therapeutic use ; RADIOLOGY AND NUCLEAR MEDICINE ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Sclerotherapy - methods ; SURGERY ; THERAPY ; Treatment Outcome</subject><ispartof>Cardiovascular and interventional radiology, 2003-01, Vol.26 (1), p.31-36</ispartof><rights>2003 INIST-CNRS</rights><rights>Springer-Verlag New York, Inc. 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-9defc1ed517fe77f988f70c677d30d7470f652ee732add5566ef8bfb675535423</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14604560$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12491020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21088421$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>RAUTIO, Riitta</creatorcontrib><creatorcontrib>KESKI-NISULA, Leo</creatorcontrib><creatorcontrib>LARANNE, Jussi</creatorcontrib><creatorcontrib>LAASONEN, Erkki</creatorcontrib><title>Treatment of lymphangiomas with OK-432 (Picibanil)</title><title>Cardiovascular and interventional radiology</title><addtitle>Cardiovasc Intervent Radiol</addtitle><description>To determine the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
The treatment was begun for 14 patients with lymphangioma. The age range of the patients at the time of the first injection was from 10 months to 42 years. Eleven of the lesions involved the head and neck region, two the thorax and one was localized in the extremity. Prior to treatment all patients were investigated with either magnetic resonance imaging, computed tomography, ultrasound or a combination of these modalities. The injections were performed with ultrasound and/or fluoroscopic guidance. Eight patients received OK-432 as first-line treatment; five were treated after surgery and one after medical therapy. On average, 2.2 intracystic injections were performed per patient. Nine of the lesions were macrocystic and five were mixed lesions.
Eleven patients showed complete or marked response to the OK-432 sclerotherapy, two patients had moderate shrinkage of their lesions and only one patient showed no response to therapy. Macrocystic lesions showed the best response to therapy. Those patients who received OK-432 as first-line treatment showed complete or marked response.
It was found that treatment of lymphangiomas with OK-432 was safe and effective.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CHEST</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>COMPUTERIZED TOMOGRAPHY</subject><subject>Diseases of the cardiovascular system</subject><subject>Female</subject><subject>HEAD</subject><subject>Humans</subject><subject>Infant</subject><subject>INJECTION</subject><subject>Lymphangioma - drug therapy</subject><subject>Lymphangioma - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>NECK</subject><subject>NMR IMAGING</subject><subject>PATIENTS</subject><subject>Picibanil - therapeutic use</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Sclerotherapy - methods</subject><subject>SURGERY</subject><subject>THERAPY</subject><subject>Treatment Outcome</subject><issn>0174-1551</issn><issn>1432-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0E1rGzEQBmBRGhrXzQ_opSwtLelByYy-9xhM0oQEkoMDuQlZK9UK--Gu1oT8-yjYYOhl5vLMi_QS8hXhDAH0eQZgGmiZFGsDlH8gMxScUTDq6SOZAWpBUUo8Jp9zfgZAaZj8RI6RiRqBwYyw5Rjc1IV-qoZYta_dZu36v2noXK5e0rSu7m9pSaxOH5JPK9en9vcXchRdm8PJfs_J49XlcnFN7-7_3Cwu7qjnhk20bkL0GBqJOgatY21M1OCV1g2HRgsNUUkWgubMNY2USoVoVnGltJRcCsbn5Mcud8hTstmnKfi1H_o--MkyBGMEw6J-7dRmHP5tQ55sl7IPbev6MGyz1RxqBVwX-P0_-Dxsx778wGqJRqpa1AXhDvlxyHkM0W7G1Lnx1SLY987trnNbpn3v3PJy820fvF11oTlc7Esu4OceuOxdG0fX-5QPTigQsrzxDRdFhXk</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>RAUTIO, Riitta</creator><creator>KESKI-NISULA, Leo</creator><creator>LARANNE, Jussi</creator><creator>LAASONEN, Erkki</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20030101</creationdate><title>Treatment of lymphangiomas with OK-432 (Picibanil)</title><author>RAUTIO, Riitta ; KESKI-NISULA, Leo ; LARANNE, Jussi ; LAASONEN, Erkki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-9defc1ed517fe77f988f70c677d30d7470f652ee732add5566ef8bfb675535423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CHEST</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>COMPUTERIZED TOMOGRAPHY</topic><topic>Diseases of the cardiovascular system</topic><topic>Female</topic><topic>HEAD</topic><topic>Humans</topic><topic>Infant</topic><topic>INJECTION</topic><topic>Lymphangioma - drug therapy</topic><topic>Lymphangioma - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>NECK</topic><topic>NMR IMAGING</topic><topic>PATIENTS</topic><topic>Picibanil - therapeutic use</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Sclerotherapy - methods</topic><topic>SURGERY</topic><topic>THERAPY</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RAUTIO, Riitta</creatorcontrib><creatorcontrib>KESKI-NISULA, Leo</creatorcontrib><creatorcontrib>LARANNE, Jussi</creatorcontrib><creatorcontrib>LAASONEN, Erkki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Cardiovascular and interventional radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RAUTIO, Riitta</au><au>KESKI-NISULA, Leo</au><au>LARANNE, Jussi</au><au>LAASONEN, Erkki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of lymphangiomas with OK-432 (Picibanil)</atitle><jtitle>Cardiovascular and interventional radiology</jtitle><addtitle>Cardiovasc Intervent Radiol</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>26</volume><issue>1</issue><spage>31</spage><epage>36</epage><pages>31-36</pages><issn>0174-1551</issn><eissn>1432-086X</eissn><coden>CAIRDG</coden><abstract>To determine the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
The treatment was begun for 14 patients with lymphangioma. The age range of the patients at the time of the first injection was from 10 months to 42 years. Eleven of the lesions involved the head and neck region, two the thorax and one was localized in the extremity. Prior to treatment all patients were investigated with either magnetic resonance imaging, computed tomography, ultrasound or a combination of these modalities. The injections were performed with ultrasound and/or fluoroscopic guidance. Eight patients received OK-432 as first-line treatment; five were treated after surgery and one after medical therapy. On average, 2.2 intracystic injections were performed per patient. Nine of the lesions were macrocystic and five were mixed lesions.
Eleven patients showed complete or marked response to the OK-432 sclerotherapy, two patients had moderate shrinkage of their lesions and only one patient showed no response to therapy. Macrocystic lesions showed the best response to therapy. Those patients who received OK-432 as first-line treatment showed complete or marked response.
It was found that treatment of lymphangiomas with OK-432 was safe and effective.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>12491020</pmid><doi>10.1007/s00270-002-1980-3</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0174-1551 |
| ispartof | Cardiovascular and interventional radiology, 2003-01, Vol.26 (1), p.31-36 |
| issn | 0174-1551 1432-086X |
| language | eng |
| recordid | cdi_osti_scitechconnect_21088421 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Antineoplastic Agents - therapeutic use Biological and medical sciences CHEST Child Child, Preschool COMPUTERIZED TOMOGRAPHY Diseases of the cardiovascular system Female HEAD Humans Infant INJECTION Lymphangioma - drug therapy Lymphangioma - pathology Male Medical sciences NECK NMR IMAGING PATIENTS Picibanil - therapeutic use RADIOLOGY AND NUCLEAR MEDICINE Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Sclerotherapy - methods SURGERY THERAPY Treatment Outcome |
| title | Treatment of lymphangiomas with OK-432 (Picibanil) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A25%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20lymphangiomas%20with%20OK-432%20(Picibanil)&rft.jtitle=Cardiovascular%20and%20interventional%20radiology&rft.au=RAUTIO,%20Riitta&rft.date=2003-01-01&rft.volume=26&rft.issue=1&rft.spage=31&rft.epage=36&rft.pages=31-36&rft.issn=0174-1551&rft.eissn=1432-086X&rft.coden=CAIRDG&rft_id=info:doi/10.1007/s00270-002-1980-3&rft_dat=%3Cproquest_osti_%3E2142833071%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=751856949&rft_id=info:pmid/12491020&rfr_iscdi=true |